EUVIMEDEUVIMED entdecken
Open Access

Venous thromboembolism risk in cancer patients receiving first‐line immune checkpoint inhibitor versus chemotherapy

Ang Li iD, Sarah B May, Jennifer La, Kylee L Martens, Christopher I Amos, Christopher R Flowers, Nhan V Do, Mary T Brophy, Vipul Chitalia, Katya Ravid, John Michael Gaziano, Nathanael R Fillmore

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26954 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Ang Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Venous Thromboembolism, Immune Checkpoint Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS, American Heart Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It remains unclear if immune checkpoint inhibitor (ICI) therapy is associated with higher rate of venous thromboembolism (VTE) compared with cytotoxic chemotherapy (chemo) in patients with comparable cancer type, staging, and comorbidities. Using the national Veterans Affairs healthcare system database from 2016 to 2021, we performed a propensity score (PS)‐weighted retrospective cohort study to compare the incidence of VTE in patients with selected stage III/IV cancer receiving first‐line ICI versus chemo. The PS model utilized overlap weights to balance age, sex, race, treatment year, VTE history, paralysis/immobilization, prolonged hospitalization, cancer type, staging, time between diagnosis and treatment, and National Cancer Institute comorbidity index. Weighted Cox regressions with robust standard error were used to assess the hazard ratio (HR) and 95% confidence interval (CI). We found that among comparable advanced cancers, first‐line ICI (n = 1823) and first‐line chemo (n = 6345) had similar rates of VTE (8.49% for ICI and 8.36% for chemo at 6 months). The weighted HR was 1.06 (95% CI 0.88–1.26) for ICI versus chemo. In a subgroup analysis restricted to lung cancers, first‐line ICI/chemo (n = 828), ICI monotherapy (n = 428), and chemo monotherapy (n = 4371) had similar rates of VTE (9.60% for ICI/chemo, 10.04% for ICI, and 8.91% for chemo at 6 months). The weighted HR was 1.05 (95% CI 0.77–1.42) for ICI versus chemo, and 1.08 (95% CI 0.83–1.42) for ICI/chemo versus chemo. In conclusion, ICI as a systemic therapy has a similarly elevated risk as cytotoxic chemo for VTE occurrence in cancer patients. This finding can inform future prospective studies exploring thromboprophylaxis strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismImmune Checkpoint InhibitorsAntineoplastic AgentsHumansNeoplasmsRetrospective StudiesIncidenceMaleFemaleMiddle AgedAgedAged, 80 and over

Substanzen

Immune Checkpoint InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA.
  • Institute for Clinical & Translational Research, Baylor College of Medicine, Houston, Texas, USA.
  • Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Hematology-Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Section of Epidemiology and Population Science, Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Ang Li

Förderung

  • NHLBI NIH HHS
  • NIH HHS
  • American Heart Association
  • Cancer Prevention and Research Institute of Texas
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Li, A., May, S. B., La, J., Martens, K. L., Amos, C. I., Flowers, C. R., Do, N. V., Brophy, M. T., Chitalia, V., Ravid, K., Gaziano, J. M., & Fillmore, N. R. (2023). Venous thromboembolism risk in cancer patients receiving first‐line immune checkpoint inhibitor versus chemotherapy. American Journal of Hematology. https://doi.org/10.1002/ajh.26954

Vancouver

Li A, May SB, La J, Martens KL, Amos CI, Flowers CR, et al. Venous thromboembolism risk in cancer patients receiving first‐line immune checkpoint inhibitor versus chemotherapy. American Journal of Hematology. 2023. doi:10.1002/ajh.26954

BibTeX
@article{Li2023,
  author = {Li, Ang and May, Sarah B and La, Jennifer and Martens, Kylee L and Amos, Christopher I and Flowers, Christopher R and Do, Nhan V and Brophy, Mary T and Chitalia, Vipul and Ravid, Katya and Gaziano, John Michael and Fillmore, Nathanael R},
  title = {Venous thromboembolism risk in cancer patients receiving first‐line immune checkpoint inhibitor versus chemotherapy},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26954}
}
Kostenlos starten →